Kangbaijia's IPO on the Shanghai Stock Exchange main board has been questioned, with its main business being pharmaceutical retail. It plans to raise 809 million yuan.

According to the Securities Times app, on July 17th, Kangbaijia Pharmaceutical Group Co., Ltd. (Kangbaijia for short) has changed its status from "under review" to "inquiry", with CITIC Securities as the sponsor institution, aiming to raise 809 million yuan through an application for listing on the main board of the Shanghai Stock Exchange.